2012
Prion-Like Behavior and Tau-dependent Cytotoxicity of β-Amyloid Oligomers Seeded by Pyroglutamylated β-Amyloid
Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T, Tayler K, Wiltgen B, Hasami A, Rönicke R, Reymann K, Hutter-Paier B, Alexandru A, Jagla W, Graubner S, Glabe CG, Demuth H-U, Bloom GS
Nature 2012, online publication May 2nd 2012
Passive Immunization against Pyroglutamate-3 Amyloid-β Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study
Frost JL, Liu B, Kleinschmidt M, Schilling S, Demuth H-U, Lemere CA
Neurodegenerative Dis. 2012, 10, 265-70.
Pyroglutamate Abeta Aggravates Behavioral Deficits in 5XFAD Mice
Wittnam JL, Portelius E, Zetterberg H, Gustavsson MK, Schilling S, Koch B, Demuth H-U, Blennow K, Wirths O, Bayer TA
J. Biol. Chem. 2012, 287, 8154–8162.
No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease.
Hillmann A, Hahn S, Schilling S, Hoffmann T, Demuth H-U, Bulic B, Schneider-Axmann T, Bayer TA, Weggen S
Neurobiology of Aging 2012, 33, 833.e39-833.e50
N-terminal Pyroglutamate (pGlu) formation of Aβ38 and Aβ40 Enforces Oligomer Formation and Potency to Disrupt Hippocampal LTP
Schlenzig D, Rönicke R, Cynis H, Ludwig H-H, Scheel E, Reymann K, Saido T, Hause G, Schilling S, Demuth H-U
J. Neurochemistry 2012, 121, 774-784